The fourth annual BRDS on genome editing and silencing for precision medicines

Drug Deliv Transl Res. 2018 Feb;8(1):266-272. doi: 10.1007/s13346-017-0457-5.

Abstract

Precision medicine is promising for treating human diseases, as it focuses on tailoring drugs to a patient's genes, environment, and lifestyle. The need for personalized medicines has opened the doors for turning nucleic acids into therapeutics. Although gene therapy has the potential to treat and cure genetic and acquired diseases, it needs to overcome certain obstacles before creating the overall prescription drugs. Recent advancement in the life science has helped to understand the effective manipulation and delivery of genome-engineering tools better. The use of sequence-specific nucleases allows genetic changes in human cells to be easily made with higher efficiency and precision than before. Nanotechnology has made rapid advancement in the field of drug delivery, but the delivery of nucleic acids presents unique challenges. Also, designing efficient and short time-consuming genome-editing tools with negligible off-target effects are in high demand for precision medicine. In the fourth annual Biopharmaceutical Research and Development Symposium (BRDS) held at the University of Nebraska Medical Center (UNMC) on September 7-8, 2017, we covered different facets of developing tools for precision medicine for therapeutic and diagnosis of genetic disorders.

Keywords: Drug delivery; Genome-editing; Immunotherapy; Nanomedicines; Precision medicine.

Publication types

  • Congress
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Drug Delivery Systems
  • Gene Editing*
  • Humans
  • Immunotherapy
  • Nanomedicine
  • Precision Medicine*